FrankMiltonBalisMD

Pediatric Hematology & Oncology • Philadelphia, PA

Professor, Pediatrics, Perelman School of Medicine

Join to view full profile

Dr. Balis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Balis' full profile

Already have an account?

Office
3401 Civic Center Blvd
Children's Hospital Of Philadelphia - Hem/Onc
Philadelphia, PA 19104
Phone+1 215-426-5414

Summary

Dr. Frank Balis is a pediatric hematologist and oncologist based in Philadelphia, PA, with a focus on clinical pharmacology of anticancer drugs in children. He completed his medical education and training at Vanderbilt University, with fellowships in Pediatric Hematology/Oncology at the University of Washington and the National Cancer Institute. His research has been widely published in journals such as Journal of Clinical Oncology and Cancer, covering topics related to the pharmacokinetics of new and conventional anticancer drugs in children and the central nervous system pharmacology of anticancer drugs. Dr. Balis is also involved in multiple clinical trials, including studies focused on the development of new drugs for childhood cancers.

Education & Training

National Capital ConsortiumFellowship, Pediatric Hematology/Oncology, 1982 - 1985
University of WashingtonFellowship, Pediatric Hematology/Oncology, 1978 - 1981
Vanderbilt University Medical CenterResidency, Pediatrics, 1975 - 1978
Vanderbilt University School of MedicineClass of 1975

Certifications & Licensure

PA State Medical License 2009 - 2024
MD State Medical License 1982 - 2016
WA State Medical License 1978 - 1982
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma Start of enrollment: 2000 Mar 01
Completed
Phase 1
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies Start of enrollment: 2008 Jul 17
Recruiting
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
Recruiting
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma Start of enrollment: 2008 Feb 04
Completed
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Start of enrollment: 2009 Jul 13
Active, not recruiting
Phase 3
Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma Start of enrollment: 2011 May 26
Completed
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients Start of enrollment: 2012 Jun 01
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor Start of enrollment: 2020 Jan 22
Active, not recruiting
Phase 1, Phase 2
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma Start of enrollment: 2020 Mar 04
Terminated
Phase 1, Phase 2
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma Start of enrollment: 2020 Nov 09
Active, not recruiting
Phase 1, Phase 2
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Start of enrollment: 2020 Apr 06
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis.
Frank M Balis, Elizabeth Rieger, Nancy J Bunin, JoAnn Gardiner, Leslie M Shaw
Cancer Chemotherapy and Pharmacology. 2025-02-11
Atypical presentations of RECQL4-related syndromes.
Liron D Grossman, Sarah Baldino, Kristin Zelley, Frank Balis, Rochelle Bagatell
Pediatric Blood & Cancer. 2024-12-01
Roadmap for the next generation of Children's Oncology Group rhabdomyosarcoma trials.
Jonathan L Metts, Jamie M Aye, Jacquelyn N Crane, Sapna Oberoi, Frank M Balis
Cancer. 2024-11-15

Lectures

GD2 as a circulating tumor biomarker (CTB) for neuroblastoma (NBL).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

A Pharmacologically-Based Approach to High Dose Methotrexate Administration to Investigate Nephrotoxicity and Acute Kidney Injury Biomarkers in Children and Adolescents with Newly Diagnosed OsteosarcomaMarch 7th, 2021

Grant Support

Fluorescent Pteridine Nucleoside AnalogsDivision Of Clinical Sciences - Nci2009
Anticancer Drug Development For Childhood CancersDivision Of Clinical Sciences - Nci2009
Clinical Pharmacology Of Anticancer DrugsDivision Of Basic Sciences - Nci2009
Clinical Pharmacology Of Anticancer DrugsNational Cancer Institute2008
Anticancer Drug Development For Childhood CancersNational Cancer Institute2008
Drug Development And Clinical Pharmacology Of Anticancer Drugs For Childhood CanNational Cancer Institute2007
Drug Development And Clinical Pharmacology Of AnticancerDivision Of Clinical Sciences - Nci2001–2006
Drug Development &Clinical Pharma. Of Anticancer DrugsDivision Of Clinical Sciences - Nci2004
Drug Development &Clinical Pharmacology Of Anticancer DDivision Of Clinical Sciences - Nci2000
Drug Development And Clinical Pharmacology Of Anticancer And Antiretroviral DrugsDivision Of Clinical Sciences - Nci1999
Clinical Pharmacology Of Anticancer And Antiretroviral DrugsDivision Of Clinical Sciences - Nci1996–1998